Online Newspapers, Live TV Channels, Radios

World Media Directory Media Directory, Journalism Jobs, Social Media, CNN News, BBC Weather, BBC World News, CBS, Health Insurance, Insurance in USA, Life Insurance, USA News, Daily News, Fox, Bangladesh News, India News, Pakistan News, Latest News

Home » Latest News » South Africa and Kenya set the stage for groundbreaking clinical trials to improve treatment for newborn babies with sepsis

South Africa and Kenya set the stage for groundbreaking clinical trials to improve treatment for newborn babies with sepsis

all media link

By ASHOK RAMSARUP :: South Africa and Kenya have set the tone for an international clinical trial to evaluate much-needed new anti-biotic combinations for newborn babies with sepsis.  The pre-trials are underway in three public hospitals on the African continent. 

The trial is sponsored by the Global Anti-biotic Research and Development Partnership (GARDP) in collaboration with the Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL); St George’s, University of London (SGUL); and Penta.

GARDP announced that the trial will be expanded to other countries in the new year, in the hope of recruiting up to 3,000 newborns overall.

GARDP says the NeoSep1 trial will evaluate new combinations of existing anti-biotics and compare them to treatment regimens that are currently used in newborn babies with suspected neo-natal sepsis. The three hospitals – Chris Hani Baragwanath Academic Hospital in Johannesburg, Tygerberg Hospital in Cape Town and KEMRI, Kilifi County Hospital in Kenya are involved in the initial stage of the clinical trial.

Neonatal sepsis is a serious condition – a life-threatening infection, affecting up to three million babies a year globally. This is compounded by the fact that an increasing number of newborns are becoming resistant to WHO-recommended anti-biotic treatments, particularly the ampicillin-gentamicin regimen. 

In the past decade, Anti-microbial Resistance (AMR) has worsened to the point that around 50-70% of common pathogens exhibit a high degree of resistance to available first-and-second-line antibiotics. Over 214,000 newborn babies die of drug-resistant neo-natal sepsis annually, mostly in low-and-middle-income countries.

Representing the organization, GARDP Research and Development Director Seamus O’Brien said: “Many babies are dying because of limited treatment options.  Now that the NeoSep1 trial is underway it shifts this trajectory by identifying new anti-biotic combinations that researchers can tailor to treat neo-natal sepsis in settings where there is widespread resistance to current recommended options. 

O’Brien said: “This is vital if we are going to address the impact of anti-microbial resistance on the burden of disease related to neo-natal sepsis.”

According to GARDP, the trial will rank the safety and efficacy of three new combinations of older antibiotics (fosfomycin-amikacin, flomoxef-amikacin, and flomoxef-fosfomycin) against the current standard of care. It will also assess and validate the doses of two antibiotics (fosfomycin and flomoxef) for use in newborns.

GARDP said the key goal was to find out whether some anti-biotic treatments perform better than others for the empiric treatment of babies with neonatal sepsis, particularly in LMICs where highly resistant bacteria were common. The trial will also consider how these combination treatments can best be used in a hospital environment with varying levels of antibiotic resistance.

A new way of comparing antibiotic treatments with each other, called the Personalised Randomised Controlled Trial (PRACTical) design will be used. The novelty of this design is that it allows researchers to compare many antibiotic treatments for neonatal sepsis. It will also enable doctors to choose treatment regimens that are likely to work well for newborns in their hospital settings.

“The development pipeline for new antibiotic treatments is limited and the lack of a universal, effective standard of care creates huge challenges in conducting research to tackle neonatal sepsis. Novel trial designs such as the PRACTical design have been specifically developed to address these challenges in important public health emergencies such as neonatal sepsis,” Sarah Walker Professor of Medical Statistics and Epidemiology at the MRC CTU at UCL.  

The NeoSep1 trial builds on findings from a global observational study of sepsis in newborn babies, conducted by GARDP and partners in 19 hospitals across 11 countries from 2018 to 2020, according to a report published by GARDP on the study in 2022.

The study found a disturbing wide variation in treatment and frequent switching of anti-biotics because of high resistance to treatments. 

Dr Julia Bielicki, paediatrician and researcher at the Centre for Neonatal and Paediatric Infection at St George’s, University of London said: “Newborns handle medicines very differently to older infants, children and adolescents. Premature or otherwise critically ill babies are at great risk of severe infection or sepsis because of their immature immune systems.  The types of bacteria causing newborn infections are not necessarily the same as those found in other patients. For these reasons, it is essential to investigate antibiotic treatments of newborns with sepsis.”

The trial aims to generate relevant and reliable evidence for doctors who need to make treatment decisions.

Adrie Bekker, Principal Investigator for the NeoSep1 trial at Tygerberg Hospital, Cape Town, and Professor in the Division of Neonatology, Department of Paediatrics and Child Health at Stellenbosch University said: “We often have to treat babies with a combination of the anti-biotics of last resort. On top of this we are not 100% sure about how to dose these drugs. We’re dealing with fragile newborns, so we need to be aware of the potential toxicity of the antibiotics and dosages we use. 

“This trial will help in giving us confidence that we are delivering more effective treatment. This is critical as we want the best possible outcome for newborns in our care,” said Professor Bekker.

Expanding the number of suitable, effective treatment regimens could be lifesaving for newborns and Christina Obiero, Principal Investigator for the NeoSep1 trial for the KEMRI-Wellcome Trust Research Programme at Kilifi County Hospital, Kenya in his view said: “Having the right antibiotics immediately can make the difference between life and death. We are hoping the trial will provide robust evidence that the antibiotic combinations are safe and effective and that this will lead to a change in both World Health Organisation (WHO) and local treatment guidelines.” 

all media link

Leave a Reply

Your email address will not be published. Required fields are marked *